Medtronic plc (MDT-Q1FY21) – Product approvals and launches expected to lead the growth of the company.

in , on October 31, 2020

Medtronic plc | is experiencing the benefit of new product launches as pipeline kicks in across the company. They had over 130 regulatory approvals this calendar year in the US, Europe, Japan, and China. Procedure volumes began to recover this quarter in multiple markets around the world, and drove market share gains in a number of largest businesses.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY21 Results Overview
– Q1FY21 Segment Performance
– Q1FY21 Key Developments
– FY21 Guidance
– Conclusion
– GAAP to Non GAAP Reconciliation

 Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio \
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance 

CrispIdea Coverage Chart 

No of Pages : 41

Release Information

  • Released

    October 31, 2020

  • Last Updated

    November 2, 2020